Daniel Przybysz M.D.
@przybyszmd
Followers
382
Following
6K
Statuses
1K
Clinical Director and Head of Radiation Oncology RadioSerra Radiation Oncology
Rio de Janeiro, Brazil
Joined October 2018
RT @gusviani: 🎙️ Fewer Sessions, Same Results? The Case for Two-Fraction SBRT in Prostate Cancer Treatment @OncoAlert 📌 Objective •Compar…
0
16
0
World cancer day. We all fight for it. 🥊 💪🏾Thanks @tvglobo for the support. #TVGlobo #RadOnc #WorldCancerDay
0
1
3
RT @ArndtVogel: Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: @NatureMedicine 🔎BREAKWA…
0
47
0
RT @KatsuakiMaehara: 🫁 Immunotherapy trials in resectable NSCLC 🫁 🌟 Updated clinical data as of January, 2025 🌟 KEYNOTE-671 - 4 year upda…
0
67
0
RT @ESTRO_RT: 📅 The deadline to apply as a mentee for the ESTRO #Mentoring Programme has been extended to 20 Feb! 🚀Connect with experienced…
0
6
0
Our team @RadioSerraRadiationTherapy has started this year on fire! 🔥 LETS GO! #ASCO #ASCO2025 #RadioSerra #RadOnc @ASCO
0
0
3
RT @gusviani: 🚨Breaking Barriers in Global Oncology❗️@OncoAlert @TheLancetOncol @fabiomoraesmd @RadioOncologia We proudly introduce the…
0
30
0
RT @ASTRO_org: New in #practicalRO: Patterns of recurrence following radiation and ADT for pathologic lymph node positive prostate cancer:…
0
7
0
RT @gusviani: 🔥 Revolutionizing Prostate Cancer Treatment: Is SABR the gold standard ? @OncoAlert 🎯 Objective •Evaluate the long-term outc…
0
38
0
RT @drdavidpalma: Hey #radonc community! The Red Journal @IJROBP is calling for papers for a new special issue: SBRT - From Clinical Tria…
0
36
0
Today we are all dressed up! Thanks for the wonderful pin and congrats on this GREAT work. #hearher @Florez_Lab
1
1
20
RT @StephenChunMD: Tune into today to virtual @NRGonc social media workshop at 1 PM EST/12:00 PM CST for an update on the NRG Oncology Podc…
0
2
0
RT @IJROBP: 1/6 We selected five Editor's Choice articles from the last several months, based on importance to the multidisciplinary oncolo…
0
24
0
RT @gusviani: Timing matters? ⏰ Morning ☢️⬆️ survival in NPC without added toxicity. Should we rethink RT scheduling? 🤔@OncoAlert 🎯Objecti…
0
21
0
RT @DrewMoghanaki: Look no further to learn which battlefront needs the most help. Hint: it isn’t prostate cancer.
0
54
0
RT @DrChoueiri: And NOW, TOP 5 PROSTATE CANCER trials of 2024! 1) The ARANOTE trial shows darolutamide + ADT improves rPFS in mHSPC by 46%…
0
173
0
RT @gusviani: 🎙 SABR-alone may be a reasonable alternative for #oligometastatic #HNSCC patients❗️ @OncoAlert 🎯 Objective: •Assess the fea…
0
26
0
RT @piet_ost: I think everyone should read this review of radiotherapy vs systemic trials and endpoints selected. Why is the world focused…
0
30
0